[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Omphis Foundation\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100545211",false,"NCT06378944","Selective Sentinella Lymph Node Biopsy with Indocyanine Green in Patients with Breast Cancer","INDOCYANINE GREEN for SELECTIVE SENTINELLA AXILLARY LYMPH NODE BIOPSY in PATIENTS with BREAST CANCER","INSEAN","Inclusion Criteria:\n\n* Patients \\>18 years of age with breast cancer who are candidates for sentinel lymph node detection will be included.\n* N0 patients or patients who have undergone target axillary detection with good response\n\nExclusion Criteria:\n\n* Lymphadenectomy","ALL","18 Years","120 Years",{"count":20,"type":21},15000,"ESTIMATED","2 Years","OBSERVATIONAL","The current observational study aims to perform the sentinel lymph node in breast cancer in the usual way with technetium 99 and add a second tracer, indocyanine green. The objective is to evaluate the detection rate of the lymph node with indocyanine green compared to the usual technique.",[26],"Breast Cancer",[28,29,30],"lymph node detection","indocyanine green","breast cancer","RECRUITING","2024-09-08",{"date":34,"type":35},"2024-09-19","ACTUAL",{"date":37,"type":35},"2024-01-01",{"date":39,"type":21},"2029-01-01",{"name":41,"class":42},"Omphis Foundation","OTHER",1,{"id":45,"slug":4,"hasResults":10,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":10,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":43},"100460801","NCT05280353","Use of Glubran 2 ® in Axillary Lymphadenectomy Without Drain","Seroma Control in Axillary Lymphadenectomy With Glubran 2® Without Drain. Multicenter, Prospective, Randomized Clinical Trial. GALA-ND Study (Glu Axillary Lymphadenectomy Ambulatory- no Drain)","GALA","Inclusion Criteria:\n\n* Over 18 years old\n* Conservative surgery for breast cancer with associated axillary lymphadenectomy\n\nExclusion Criteria:\n\n* Mastectomy\n* History of axillary surgery or ipsilateral axillary radiotherapy\n* ASA 4 patients. (ASA 3 patients selected)\n* Lack of adequate cognitive capacity and\u002For signed informed consent\n* Pregnancy","FEMALE",{"count":53,"type":21},134,"INTERVENTIONAL",[56],"NA","Axillary lymphadenectomy in breast cancer continues to be a common practice in certain patients. The use of sealants and drains continues to be a source of disagreement among the scientific community. That is why the study was designed to show whether the sealant reduces seroma after axillary lymphadenectomy without drainage.",[59],"Seroma Following Procedure","2024-09-02",{"date":62,"type":35},"2024-09-04",{"date":64,"type":35},"2022-04-01",{"date":66,"type":21},"2026-06-01",{"name":41,"class":42},""]